LYV — Live Nation Entertainment, Inc.

The Q2 2026 beat (revenue $7.67B, EPS $1.05 vs. ~$0.66 expected), 49M fans attended (+10%), Ticketmaster AOI +14%, and raised guidance have kept the Street bullish. Consensus is Buy with a $208.18 average target and recent targets up to $222. Insider selling and the DOJ verdict keep sentiment from being euphoric, but the dominant tone is constructive.

Revenue growth is stable but slightly cooling: YoY was +11.1% in Q3 2025, +11.1% in Q4 2025, +12.1% in Q1 2026, and +9.4% in Q2 2026. The Q1-to-Q2 sequential revenue jump (+102% in 2026) is normal seasonal touring behavior rather than an anomaly, although the magnitude is larger than a year earlier. TTM operating margin is just 3.4% and was depressed by the ~$450M Q1 2026 DOJ accrual; excluding that, the live-event economics remain stable, with Q2 2026 operating income of $513M and record deferred revenue pointing to solid H2 2026.

At $180.64 as of 2026-08-27, LYV trades at 1.60x trailing revenue versus its 5-year average P/S of 1.73x, so it is modestly cheaper than its own history. The negative TTM P/E and 6.7x PEG are mostly artifacts of the legal charge and near-zero equity; on normalized earnings, the multiple is still high in absolute terms. This is a 'less expensive than usual' call, not a cheap stock on an absolute basis.

The market is underweighting trailing GAAP earnings and overweighting the record deferred revenue ($6.4B, +25% YoY) and 2027 growth. At $180.64, the stock is about 13% below the $208 consensus target, so the play is that normalized earnings power grows into the multiple and the legal overhang fades. If the antitrust remedy lands harshly or 2027 guidance disappoints, the same multiple can compress and $180 will no longer look inexpensive.

As of 2026-08-27, RSI was 47.6, neutral; price was 1.3% below the 20-day SMA, essentially flat at -0.06% versus the 50-day SMA, and 13.4% above the 200-day SMA. This is a consolidating uptrend, not overbought. The 50-day area around $180.7 is the near-term pivot, with $189.25 as overhead resistance; a close above $189 or a dip toward the rising 200-day would offer a cleaner entry timing signal.

• Consumer resilience in live entertainment – management reported zero observed spending pullback and a historic low 1.1% cancellation rate vs. a 1.6% historical average.
• Regulatory/antitrust environment – the April 2026 DOJ jury verdict and ongoing state scrutiny over ticketing fees and bundling create a persistent legal overhang.
• Interest rates and discount rates – with $6.23B long-term debt and near-zero equity, LYV is sensitive to rate-driven multiple compression and interest costs.
• International expansion – international markets drove roughly 70% of Ticketmaster AOI growth and 80% of sponsorship AOI growth in Q2, adding FX and regulatory complexity.
• Inflation and event costs – pricing power at venues and premium sponsorships has held so far, but cost inflation in artists, production, and labor is a margin risk.

• Goldman Sachs Communacopia & Technology Conference on September 9, 2026 – management's 2027 bookings and late-2026 pacing update.
• Q3 2026 earnings expected late October/early November – conversion of the record $6.4B deferred revenue during peak summer touring volume.
• Antitrust remedy phase or settlement – a contained remedy would remove the stock's biggest overhang; a harsh remedy would pressure it further.
• International and sponsorship momentum – continued double-digit international growth is the primary AOI engine.

• Antitrust remedy risk – a federal jury already found Live Nation and Ticketmaster liable in April 2026; conduct restrictions, damages, or structural remedies are possible.
• Balance sheet fragility – stockholders' equity is only $82M, current ratio is 0.85, and long-term debt is $6.23B, leaving little cushion for an adverse shock.
• Consumer spending reversal – demand is strong now, but a recession would directly hit attendance, fee-bearing tickets, and venue spending.
• Insider selling – trailing 12-month insider activity skews entirely to sells, including a CAO sale at $184 in late August 2026, with zero open-market buys.

LYV's core operations are objectively strong right now: attendance is at records, deferred revenue is at an all-time high, and pricing power remains intact. But the stock already trades near the lower end of analyst targets, and the unresolved antitrust liability plus near-zero equity cap multiple expansion. As of 2026-08-27, this is a balanced hold—more upside if the remedy is benign, more downside if legal costs or restrictions escalate.

Calculated by applying LYV's 5-year average P/S of 1.73x to trailing twelve-month revenue of $26.27B, implying a market cap of ~$45.4B, or ~$195.3 per share on ~232.7M shares. I used trailing rather than forward revenue because the unresolved antitrust remedy and near-zero equity justify discounting the historical multiple versus the higher forward-based consensus target.